Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

- Non-GAAP EPS of $2.13 topped estimates by $0.11 in Q2 2025; GAAP revenue of $15.8 billion missed by $93 million in Q2 2025. - KEYTRUDA oncology drug sales climbed 9% in Q2 2025, while GARDASIL ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

The federal government is recommending flu vaccines remove the preservative thimerosal after Health and Human Services ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...